GHRP-2 (Pralmorelin)

Description

Disclaimer: This compound is provided strictly for laboratory and scientific research purposes only. It is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use, including ingestion, injection, or any form of administration.

WADA Notice: GHRP-2 is prohibited under WADA S2.2.4 (Growth Hormone-Releasing Peptides), in- and out-of-competition, on the 2026 WADA Prohibited List.

Chemical Properties of the Compound

Overview

GHRP-2 (INN: pralmorelin) is a synthetic hexapeptide and potent GHS-R1a (ghrelin receptor) agonist developed from enkephalin SAR studies. Contains 3 unnatural D-amino acids (D-Ala, D-β-Nal, D-Phe) conferring enzymatic resistance. Unlike the selective ipamorelin, GHRP-2 co-stimulates ACTH and cortisol at GH-releasing concentrations in preclinical models – a key research design distinction. Not FDA-approved. WADA S2.2.4. Supplied for laboratory research only.

Working Mechanism of GHRP-2

GHS-R1a/Gq/PLCβ/IP3/Ca²⁺/GH Exocytosis: GHS-R1a binding → Gq/11 → PLCβ → IP3 → ER Ca²⁺ release → GH vesicle exocytosis from somatotrophs. Published data (Muccioli et al. 2007, PMID 17622734) document GHS-R1a as a Gq-preferring GPCR activated by ghrelin and synthetic GHRPs.

Non-Selective Profile (ACTH/Cortisol Co-Stimulation): Unlike ipamorelin (selective; no ACTH/cortisol at 200× ED50, Raun et al. 1998, PMID 9849822), GHRP-2 co-stimulates ACTH and cortisol at GH-releasing concentrations. This non-selective profile must be controlled in studies with adrenal endpoints and is a key mechanistic variable in GHRP-2 vs ipamorelin comparative research.

Research Findings / Research Applications

•       GHS-R1a high-potency reference agonist: competitive binding displacement and Gq/Ca²⁺ mobilisation assays
•       GHRP-2 vs ipamorelin selectivity comparison: ACTH/cortisol co-stimulation quantification in primary pituitary cell cultures
•       GH secretagogue SAR research: GHRP-2 as non-selective GHS-R1a agonist reference for structure-activity comparisons
•       Synergistic GH release: GHRP-2 + CJC-1295 DAC co-administration in somatotroph Gs/cAMP + Gq/Ca²⁺ convergence research

Note: These findings are based on early-stage and preclinical research. Results are not consistent across all models, and data remains limited without validation in human clinical settings.

Risks & Handling Information

•       PPE: gloves, lab coat, eye protection. Handle as a CNS-active neuroendocrine peptide. Reconstitute aseptically in water or 0.1% acetic acid.
•       Risk Tier: HIGH – Potent GHS-R1a agonist; GH, ACTH, cortisol stimulation documented. No human safety data. No long-term toxicity data. GH axis dependency potential plausible but uncharacterised.
•       −20°C sealed, light-protected. Stable ~2–4 weeks reconstituted at 2–8°C.

FAQs

How does GHRP-2 differ from ipamorelin?

Both activate GHS-R1a via Gq/Ca²⁺. GHRP-2 co-stimulates ACTH and cortisol; ipamorelin is selective (no ACTH/cortisol at 200× ED50). GHRP-2 is preferred for broad GHS-R1a co-stimulation research; ipamorelin for isolated GH axis activation.

References

•       Muccioli G, Baragli A, Granata R, Papotti M, Ghigo E. Heterogeneity of ghrelin/growth hormone secretagogue receptors. Frontiers in Neuroendocrinology. 2007;28(4):215–228. https://pubmed.ncbi.nlm.nih.gov/17622734/
•       Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Contact us at 419-707-5450 or support@bc9.co. 

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.